Club cells form lung adenocarcinomas and maintain the alveoli of adult mice

  1. Magda Spella  Is a corresponding author
  2. Ioannis Lilis
  3. Mario AA Pepe
  4. Yuanyuan Chen
  5. Maria Armaka
  6. Anne-Sophie Lamort
  7. Dimitra E Zazara
  8. Fani Roumelioti
  9. Malamati Vreka
  10. Nikolaos I Kanellakis
  11. Darcy E Wagner
  12. Anastasios D Giannou
  13. Vasileios Armenis
  14. Kristina AM Arendt
  15. Laura V Klotz
  16. Dimitrios Toumpanakis
  17. Vassiliki Karavana
  18. Spyros G Zakynthinos
  19. Ioanna Giopanou
  20. Antonia Marazioti
  21. Vassilis Aidinis
  22. Rocio Sotillo
  23. Georgios T Stathopoulos  Is a corresponding author
  1. University of Patras, Greece
  2. Helmholtz Center Munich, Germany
  3. German Cancer Research Center (DKFZ), Germany
  4. Biomedical Sciences Research Center Alexander Fleming, Greece
  5. Evangelismos Hospital, Greece

Abstract

Lung cancer and chronic lung diseases impose major disease burdens worldwide and are caused by inhaled noxious agents including tobacco smoke. The cellular origins of environmental-induced lung tumors and of the dysfunctional airway and alveolar epithelial turnover observed with chronic lung diseases are unknown. To address this, we combined mouse models of genetic labeling and ablation of airway (club) and alveolar cells with exposure to environmental noxious and carcinogenic agents. Club cells are shown to survive KRAS mutations and to form lung tumors after tobacco carcinogen exposure. Increasing numbers of club cells are found in the alveoli with aging and after lung injury, but go undetected since they express alveolar proteins. Ablation of club cells prevents chemical lung tumors and causes alveolar destruction in adult mice. Hence club cells are important in alveolar maintenance and carcinogenesis and may be a therapeutic target against premalignancy and chronic lung disease.

Data availability

All raw data produced in this study are provided as *.xlsx source data Supplements. The microarray data produced by this study were deposited at GEO (http://www.ncbi.nlm.nih.gov/geo/; Accession ID: GSE94981). Previously reported [36-40] murine ATII and human AEC, ATII, AMΦ, non-smokers lung, and LUAD microarray data are available at GEO using Accession IDs GSE82154, GSE55459, GSE46749, GSE18816, and GSE43458).

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Magda Spella

    Department of Physiology, University of Patras, Rio, Greece
    For correspondence
    magsp@upatras.gr
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2505-7778
  2. Ioannis Lilis

    Department of Physiology, University of Patras, Rio, Greece
    Competing interests
    The authors declare that no competing interests exist.
  3. Mario AA Pepe

    Comprehensive Pneumology Center (CPC), Helmholtz Center Munich, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
  4. Yuanyuan Chen

    Division of Molecular Thoracic Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  5. Maria Armaka

    Institute of Immunology, Biomedical Sciences Research Center Alexander Fleming, Vari, Greece
    Competing interests
    The authors declare that no competing interests exist.
  6. Anne-Sophie Lamort

    Comprehensive Pneumology Center (CPC), Helmholtz Center Munich, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
  7. Dimitra E Zazara

    Department of Physiology, University of Patras, Rio, Greece
    Competing interests
    The authors declare that no competing interests exist.
  8. Fani Roumelioti

    Institute of Immunology, Biomedical Sciences Research Center Alexander Fleming, Vari, Greece
    Competing interests
    The authors declare that no competing interests exist.
  9. Malamati Vreka

    Department of Physiology, University of Patras, Rio, Greece
    Competing interests
    The authors declare that no competing interests exist.
  10. Nikolaos I Kanellakis

    Department of Physiology, University of Patras, Rio, Greece
    Competing interests
    The authors declare that no competing interests exist.
  11. Darcy E Wagner

    Comprehensive Pneumology Center (CPC), Helmholtz Center Munich, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
  12. Anastasios D Giannou

    Department of Physiology, University of Patras, Rio, Greece
    Competing interests
    The authors declare that no competing interests exist.
  13. Vasileios Armenis

    Department of Physiology, University of Patras, Rio, Greece
    Competing interests
    The authors declare that no competing interests exist.
  14. Kristina AM Arendt

    Comprehensive Pneumology Center (CPC), Helmholtz Center Munich, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
  15. Laura V Klotz

    Comprehensive Pneumology Center (CPC), Helmholtz Center Munich, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
  16. Dimitrios Toumpanakis

    1st Department of Critical Care Medicine and Pulmonary Services, Evangelismos Hospital, Athens, Greece
    Competing interests
    The authors declare that no competing interests exist.
  17. Vassiliki Karavana

    1st Department of Critical Care Medicine and Pulmonary Services, Evangelismos Hospital, Athens, Greece
    Competing interests
    The authors declare that no competing interests exist.
  18. Spyros G Zakynthinos

    1st Department of Critical Care Medicine and Pulmonary Services, Evangelismos Hospital, Athens, Greece
    Competing interests
    The authors declare that no competing interests exist.
  19. Ioanna Giopanou

    Department of Physiology, University of Patras, Rio, Greece
    Competing interests
    The authors declare that no competing interests exist.
  20. Antonia Marazioti

    Department of Physiology, University of Patras, Rio, Greece
    Competing interests
    The authors declare that no competing interests exist.
  21. Vassilis Aidinis

    Institute of Immunology, Biomedical Sciences Research Center Alexander Fleming, Vari, Greece
    Competing interests
    The authors declare that no competing interests exist.
  22. Rocio Sotillo

    Division of Molecular Thoracic Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0855-7917
  23. Georgios T Stathopoulos

    Department of Physiology, University of Patras, Rio, Greece
    For correspondence
    gstathop@upatras.gr
    Competing interests
    The authors declare that no competing interests exist.

Funding

H2020 European Research Council (260524)

  • Georgios T Stathopoulos

Hellenic State Scholarship Foundation (Post-doctoral Research Fellowship)

  • Magda Spella

Howard Hughes Medical Institute (International Research Scholars Award)

  • Rocio Sotillo

German Center for Lung Research

  • Kristina AM Arendt
  • Laura V Klotz
  • Georgios T Stathopoulos

Hellenic Thoracic Society (PhD Fellowship)

  • Malamati Vreka
  • Anastasios D Giannou

H2020 European Research Council (281614)

  • Rocio Sotillo

H2020 European Research Council (679345)

  • Georgios T Stathopoulos

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: Experiments were designed and approved a priori by the Veterinary Administration of the Prefecture of Western Greece (approval numbers 3741/16.11.2010, 60291/3035/19.03.2012, and 118018/578/30.04.2014) and were conducted according to Directive 2010/63/EU (http://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1486710385917&uri=CELEX:32010L0063).

Human subjects: Archival tissue samples of patients with lung adenocarcinoma were used in this study. The observational protocol for the original studies adhered to the Helsinki Declaration and was approved by the Ethics Committee of the University Hospital of Patras, and all patients gave written informed consent.

Reviewing Editor

  1. Jody Rosenblatt, King's College London, United Kingdom

Publication history

  1. Received: January 28, 2019
  2. Accepted: May 24, 2019
  3. Accepted Manuscript published: May 29, 2019 (version 1)
  4. Version of Record published: July 2, 2019 (version 2)

Copyright

© 2019, Spella et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,953
    Page views
  • 578
    Downloads
  • 31
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, Scopus, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Magda Spella
  2. Ioannis Lilis
  3. Mario AA Pepe
  4. Yuanyuan Chen
  5. Maria Armaka
  6. Anne-Sophie Lamort
  7. Dimitra E Zazara
  8. Fani Roumelioti
  9. Malamati Vreka
  10. Nikolaos I Kanellakis
  11. Darcy E Wagner
  12. Anastasios D Giannou
  13. Vasileios Armenis
  14. Kristina AM Arendt
  15. Laura V Klotz
  16. Dimitrios Toumpanakis
  17. Vassiliki Karavana
  18. Spyros G Zakynthinos
  19. Ioanna Giopanou
  20. Antonia Marazioti
  21. Vassilis Aidinis
  22. Rocio Sotillo
  23. Georgios T Stathopoulos
(2019)
Club cells form lung adenocarcinomas and maintain the alveoli of adult mice
eLife 8:e45571.
https://doi.org/10.7554/eLife.45571

Further reading

    1. Cancer Biology
    2. Computational and Systems Biology
    Jonathan Rodriguez, Abdon Iniguez ... Richard A Van Etten
    Research Article Updated

    Chronic myeloid leukemia (CML) is a blood cancer characterized by dysregulated production of maturing myeloid cells driven by the product of the Philadelphia chromosome, the BCR-ABL1 tyrosine kinase. Tyrosine kinase inhibitors (TKIs) have proved effective in treating CML, but there is still a cohort of patients who do not respond to TKI therapy even in the absence of mutations in the BCR-ABL1 kinase domain that mediate drug resistance. To discover novel strategies to improve TKI therapy in CML, we developed a nonlinear mathematical model of CML hematopoiesis that incorporates feedback control and lineage branching. Cell–cell interactions were constrained using an automated model selection method together with previous observations and new in vivo data from a chimeric BCR-ABL1 transgenic mouse model of CML. The resulting quantitative model captures the dynamics of normal and CML cells at various stages of the disease and exhibits variable responses to TKI treatment, consistent with those of CML patients. The model predicts that an increase in the proportion of CML stem cells in the bone marrow would decrease the tendency of the disease to respond to TKI therapy, in concordance with clinical data and confirmed experimentally in mice. The model further suggests that, under our assumed similarities between normal and leukemic cells, a key predictor of refractory response to TKI treatment is an increased maximum probability of self-renewal of normal hematopoietic stem cells. We use these insights to develop a clinical prognostic criterion to predict the efficacy of TKI treatment and design strategies to improve treatment response. The model predicts that stimulating the differentiation of leukemic stem cells while applying TKI therapy can significantly improve treatment outcomes.

    1. Cancer Biology
    2. Cell Biology
    Katarzyna Bogucka-Janczi, Gregory Harms ... Krishnaraj Rajalingam
    Research Advance Updated

    The actin cytoskeleton is tightly controlled by RhoGTPases, actin binding-proteins and nucleation-promoting factors to perform fundamental cellular functions. We have previously shown that ERK3, an atypical MAPK, controls IL-8 production and chemotaxis (Bogueka et al., 2020). Here, we show in human cells that ERK3 directly acts as a guanine nucleotide exchange factor for CDC42 and phosphorylates the ARP3 subunit of the ARP2/3 complex at S418 to promote filopodia formation and actin polymerization, respectively. Consistently, depletion of ERK3 prevented both basal and EGF-dependent RAC1 and CDC42 activation, maintenance of F-actin content, filopodia formation, and epithelial cell migration. Further, ERK3 protein bound directly to the purified ARP2/3 complex and augmented polymerization of actin in vitro. ERK3 kinase activity was required for the formation of actin-rich protrusions in mammalian cells. These findings unveil a fundamentally unique pathway employed by cells to control actin-dependent cellular functions.